Related Experiment Videos

Effect of MCI-186 on ischemia-induced changes in monoamine metabolism in rat brain

R Oishi1, Y Itoh, M Nishibori

  • 1Department of Pharmacology, Okayama University Medical School, Japan.

Stroke
|November 1, 1989
PubMed

Insights

MCI-186, a free radical scavenger, reduces ischemia-induced changes in brain monoamine metabolism in rats. This neuroprotective agent does not affect normal rat brains but mitigates altered dopamine and norepinephrine levels during ischemia.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Ischemia-induced brain edema is a significant concern.
  • Monoamine neurotransmitters play crucial roles in brain function.
  • Free radical scavengers are investigated for neuroprotective properties.

Purpose of the Study:

  • To investigate the effects of MCI-186 on monoamine metabolism in normal and ischemic rat brains.
  • To determine if MCI-186's neuroprotective effects are linked to alterations in neurotransmitter levels.
  • To assess MCI-186's efficacy in mitigating ischemia-induced changes in brain monoamine metabolism.

Main Methods:

  • Rats were subjected to cerebral ischemia via internal carotid artery embolization.
  • Monoamine concentrations and metabolite levels (dopamine, norepinephrine, serotonin) were measured.
  • MCI-186 was administered intravenously before or after ischemia induction.
  • Neurotransmitter turnover rates were calculated.

Main Results:

  • MCI-186 did not significantly alter monoamine metabolism in normal rats.
  • Ischemia led to increased dopamine and serotonin metabolites and decreased norepinephrine in the affected brain region.
  • MCI-186 treatment attenuated these ischemia-induced changes in monoamine metabolism.
  • Dopamine turnover was elevated post-ischemia, an effect reduced by MCI-186.

Conclusions:

  • MCI-186 attenuates ischemia-induced alterations in brain monoamine metabolism.
  • The free radical scavenging action of MCI-186 likely contributes to its neuroprotective effects.
  • MCI-186 demonstrates potential as a therapeutic agent for ischemic brain injury by modulating neurotransmitter systems.

Related Concept Videos